Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4562 ARTÍCULOS , VIENDO DEL 4111 AL 4125

Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age

Dafsari HS, Reker P, Stalinski L, Silverdale M, Rizos A, Ashkan K, Barbe MT, Fink GR, Evans J, Steffen J, Samuel M, Dembek TA, Visser-Vandewalle V, Antonini A, Ray-Chaudhuri K, Martinez-Martin P, Timmermann L; EUROPAR and the IPMDS (International Parkinson's and Movement Disorders Society) Non-Motor Parkinson's Disease Study Group.

Mov Disord. 2018 Jan;33(1):99-107. doi: 10.1002/mds.27222. Epub 2017 Nov 18.

Genetics of Parkinson's disease and related disorders

Zhang PL, Chen Y, Zhang CH, Wang YX, Fernandez-Funez P.

J Med Genet. 2018 Feb;55(2):73-80. doi: 10.1136/jmedgenet-2017-105047. Epub 2017 Nov 18.

Camptocormia: New Signs in an Old Syndrome

Tatu L, Bogousslavsky J.

Front Neurol Neurosci. 2018;42:87-95. doi: 10.1159/000475683. Epub 2017 Nov 17.

Parkinson's disease: experimental models and reality

Jiang P, Dickson DW.

Acta Neuropathol. 2018 Jan;135(1):13-32. doi: 10.1007/s00401-017-1788-5. Epub 2017 Nov 18.

Subacute corticobasal syndrome following internal carotid endarterectomy

Marques A, Bourgois N, Vidal T, Ferrier A, Mathais S, Merlin C, Valla C, De Schlichting E, Jean B, Deffond D, Durif F.

Rev Neurol (Paris). 2018 Mar;174(3):157-161. doi: 10.1016/j.neurol.2017.06.017. Epub 2017 Nov 15.

Selective autophagy: The new player in the fight against neurodegenerative diseases?

Wu MY, Song JX, Wang SF, Cai CZ, Li M, Lu JH.

Brain Res Bull. 2018 Mar;137:79-90. doi: 10.1016/j.brainresbull.2017.11.009. Epub 2017 Nov 16.

Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics

Samotus O, Kumar N, Rizek P, Jog M.

Can J Neurol Sci. 2018 Jan;45(1):11-22. doi: 10.1017/cjn.2017.260. Epub 2017 Nov 21.

A case of multiple system atrophy-parkinsonian type with stuttering- and palilalia-like dysfluencies and putaminal atrophy

Kikuchi Y, Umezaki T, Uehara T, Yamaguchi H, Yamashita K, Hiwatashi A, Sawatsubashi M, Adachi K, Yamaguchi Y, Murakami D, Kira JI, Nakagawa T.

J Fluency Disord. 2018 Sep;57:51-58. doi: 10.1016/j.jfludis.2017.11.002. Epub 2017 Nov 14.

Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis

Lattanzi S, Grillo E, Brigo F, Silvestrini M.

J Neurol. 2018 Apr;265(4):733-740. doi: 10.1007/s00415-017-8681-y. Epub 2017 Nov 20.

The immunogenetics of neurological disease

Misra MK, Damotte V, Hollenbach JA.

Immunology. 2018 Apr;153(4):399-414. doi: 10.1111/imm.12869. Epub 2017 Dec 11.

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease

LeWitt PA, Pahwa R, Sedkov A, Corbin A, Batycky R, Murck H.

J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):155-161. doi: 10.1089/jamp.2016.1354. Epub 2017 Nov 21.

Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinson's Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature

Ten Brinke TR, Odekerken VJJ, van Laar T, van Dijk JMC, Dijk JM, van den Munckhof P, Schuurman PR, de Bie RMA.

Neuromodulation. 2018 Aug;21(6):527-531. doi: 10.1111/ner.12732. Epub 2017 Nov 22.

The mitochondrial UPR: mechanisms, physiological functions and implications in ageing

Shpilka T, Haynes CM.

Nat Rev Mol Cell Biol. 2018 Feb;19(2):109-120. doi: 10.1038/nrm.2017.110. Epub 2017 Nov 22.

Pulse duration settings in subthalamic stimulation for Parkinson's disease

Steigerwald F, Timmermann L, Kühn A, Schnitzler A, Reich MM, Kirsch AD, Barbe MT, Visser-Vandewalle V, Hübl J, van Riesen C, Groiss SJ, Moldovan AS, Lin S, Carcieri S, Manola L, Volkmann J.

Mov Disord. 2018 Jan;33(1):165-169. doi: 10.1002/mds.27238. Epub 2017 Nov 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias